Aethlon Medical Inc Total Assets
Aethlon Medical Inc total assets. Based on the latest financial reports, Aethlon Medical Inc (AEMD) holds total assets worth $6.24 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Aethlon Medical Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Aethlon Medical Inc (1997–2026)
Total assets of Aethlon Medical Inc from 1997 to 2026. This chart illustrates how Aethlon Medical Inc's total assets have evolved over time, based on quarterly financial data. See Aethlon Medical Inc (AEMD) share price today for real-time trading data and today's change.
Aethlon Medical Inc - Asset Composition Analysis
Aethlon Medical Inc Total Assets Breakdown (March 2026)
Aethlon Medical Inc total assets breakdown as of March 2026. Aethlon Medical Inc's total assets of $6.24 Million consist of 87.9% current assets and 12.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1997–2026)
This chart illustrates how Aethlon Medical Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Aethlon Medical Inc working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aethlon Medical Inc's current assets represent 87.9% of total assets in 2026, a decrease from 91.2% in 1997.
- Cash Position: Cash and equivalents constituted 79.4% of total assets in 2026, down from 91.2% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1997.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aethlon Medical Inc Competitors by Total Assets
Key competitors of Aethlon Medical Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.59 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Aethlon Medical Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.42 | 2.49 | 24.19 |
| Quick Ratio | 5.42 | 2.49 | 24.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.57 Million | $2.42 Million | $22.59 Million |
Aethlon Medical Inc - Advanced Valuation Insights
This section examines the relationship between Aethlon Medical Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.23 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | -13.9% |
| Total Assets | $6.33 Million |
| Market Capitalization | $1.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aethlon Medical Inc's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Aethlon Medical Inc's assets decreased by 13.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aethlon Medical Inc (1997–2026)
The table below shows the annual total assets of Aethlon Medical Inc from 1997 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | $6.33 Million | -13.95% |
| 2025-03-31 | $7.36 Million | -10.75% |
| 2024-03-31 | $8.25 Million | -52.90% |
| 2023-03-31 | $17.51 Million | -9.83% |
| 2022-03-31 | $19.42 Million | +82.00% |
| 2021-03-31 | $10.67 Million | +2.71% |
| 2020-03-31 | $10.39 Million | +151.95% |
| 2019-03-31 | $4.12 Million | -43.92% |
| 2018-03-31 | $7.35 Million | +325.86% |
| 2017-03-31 | $1.73 Million | -32.48% |
| 2016-03-31 | $2.56 Million | +85.19% |
| 2015-03-31 | $1.38 Million | -18.55% |
| 2014-03-31 | $1.70 Million | +241.28% |
| 2013-03-31 | $496.69K | -40.78% |
| 2012-03-31 | $838.69K | +47.86% |
| 2011-03-31 | $567.22K | -12.20% |
| 2010-03-31 | $646.00K | +227.27% |
| 2009-03-31 | $197.39K | -59.56% |
| 2008-03-31 | $488.11K | -20.42% |
| 2007-03-31 | $613.36K | -40.44% |
| 2006-03-31 | $1.03 Million | +242.86% |
| 2005-03-31 | $300.35K | +6.64% |
| 2004-03-31 | $281.66K | -29.32% |
| 2003-03-31 | $398.52K | -59.06% |
| 2002-03-31 | $973.54K | -24.18% |
| 2001-03-31 | $1.28 Million | -2.73% |
| 2000-03-31 | $1.32 Million | +1508.33% |
| 1999-03-31 | $82.07K | +10785.01% |
| 1998-03-31 | $754.00 | -72.32% |
| 1997-03-31 | $2.72K | -- |
About Aethlon Medical Inc
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.